California biotech Replicate Biosciences will receive up to $550 million from Novo Nordisk in an alliance that aims to track down new drugs for obesity and diabetes. The partners will develop new ...
Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases Replicate will receive research ...
Replicate Inc., a startup making it easier for software teams to build artificial intelligence applications, today exited stealth mode and announced that it has secured $17.8 million in funding. The ...
Replicate Bioscience is a clinical-stage company amplifying the power of RNA therapeutics by pioneering its novel self-replicating RNA (srRNA) technology to overcome the shortcomings of existing mRNA ...
Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team SAN DIEGO, July 10, 2023 /PRNewswire/ -- ...
Under the agreement, Instituto Butantan will conduct registrational clinical trials of Replicate's novel srRNA rabies vaccine for post-exposure and pre-exposure prophylaxis Replicate to provide GMP ...
Replicate, a startup that runs machine learning models in the cloud, today launched out of stealth with $17.8 million in venture capital backing; $12.5 million of the total came from a Series A led by ...
Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability SAN DIEGO, Feb. 7, 2025 /PRNewswire/ -- Replicate Bioscience, a ...
Replicate Bioscience and Novo Nordisk collaborate to develop srRNA-based therapies for obesity, type 2 diabetes, and cardiometabolic diseases. Novo Nordisk receives an exclusive worldwide license to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results